ZBTB44 Knockout cell line (T24)

Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.

ZBTB44 (zinc finger and BTB domain containing 44) encodes a zinc finger and BTB domain-containing protein with predicted DNA-binding and zinc ion-binding activities. The protein is predicted to localize to the nucleus, consistent with a potential role in regulation of gene expression. However, the available annotation does not establish specific transcriptional targets or biological pathways regulated by ZBTB44.

The T24 cell line was established in 1970 from a primary grade III transitional cell carcinoma (urothelial carcinoma) of the urinary bladder from an 81-year-old female patient. This human bladder carcinoma cell line is widely characterized and has been reported to carry HRAS and p53 mutations. T24 cells produce multiple cytokines, including granulocyte colony-stimulating factor (G-CSF), interleukin-6 (IL-6), and stem cell factor (SCF). The line is commonly used as a model for studying bladder cancer biology, oncogenic signaling pathways, cytokine regulation, and therapeutic responses in urothelial carcinoma.

Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.